newsfilter
← Latest News
Business Wire·

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

  • Revvity, Inc. launched the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution for population-wide screening of type 1 diabetes (T1D) risk in children.
  • The platform utilizes dried blood spots (DBS) for simple, scalable sample collection & processes samples on Revvity's high-throughput GSP® instrument.
  • The end-to-end workflow detects at-risk individuals months or years before symptom onset to enable early intervention & disease-modifying treatment.
  • This launch expands Revvity's diagnostic offerings from newborn screening into early childhood screening programs.
  • The kit is initially available in Europe & all markets accepting CE IVD-marked products, but it is not FDA-cleared for the U.S. market.
  • Revvity will present details on T1D on-site installation & off-site testing service solutions in collaboration with Sanofi at the European Association for the Study of Diabetes (EASD) in Milan.